136 related articles for article (PubMed ID: 19519533)
1. Yeast-derived beta-glucan in combination with anti-tumor monoclonal antibody therapy in cancer.
Liu J; Gunn L; Hansen R; Yan J
Recent Pat Anticancer Drug Discov; 2009 Jun; 4(2):101-9. PubMed ID: 19519533
[TBL] [Abstract][Full Text] [Related]
2. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy.
Liu J; Gunn L; Hansen R; Yan J
Exp Mol Pathol; 2009 Jun; 86(3):208-14. PubMed ID: 19454271
[TBL] [Abstract][Full Text] [Related]
3. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.
Salvador C; Li B; Hansen R; Cramer DE; Kong M; Yan J
Clin Cancer Res; 2008 Feb; 14(4):1239-47. PubMed ID: 18281559
[TBL] [Abstract][Full Text] [Related]
4. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway.
Li B; Allendorf DJ; Hansen R; Marroquin J; Ding C; Cramer DE; Yan J
J Immunol; 2006 Aug; 177(3):1661-9. PubMed ID: 16849475
[TBL] [Abstract][Full Text] [Related]
5. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
6. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.
Yan J; Allendorf DJ; Brandley B
Expert Opin Biol Ther; 2005 May; 5(5):691-702. PubMed ID: 15934844
[TBL] [Abstract][Full Text] [Related]
7. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
Hong F; Yan J; Baran JT; Allendorf DJ; Hansen RD; Ostroff GR; Xing PX; Cheung NK; Ross GD
J Immunol; 2004 Jul; 173(2):797-806. PubMed ID: 15240666
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor monoclonal antibodies in conjunction with β-glucans: a novel anti-cancer immunotherapy.
Xiang D; Sharma VR; Freter CE; Yan J
Curr Med Chem; 2012; 19(25):4298-305. PubMed ID: 22834812
[TBL] [Abstract][Full Text] [Related]
9. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
10. Effects of beta-glucans on the immune system.
Akramiene D; Kondrotas A; Didziapetriene J; Kevelaitis E
Medicina (Kaunas); 2007; 43(8):597-606. PubMed ID: 17895634
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy.
Driscoll M; Hansen R; Ding C; Cramer DE; Yan J
Cancer Biol Ther; 2009 Feb; 8(3):218-25. PubMed ID: 19106638
[TBL] [Abstract][Full Text] [Related]
12. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.
Li B; Allendorf DJ; Hansen R; Marroquin J; Cramer DE; Harris CL; Yan J
Cancer Res; 2007 Aug; 67(15):7421-30. PubMed ID: 17671212
[TBL] [Abstract][Full Text] [Related]
13. Specificity of membrane complement receptor type three (CR3) for beta-glucans.
Ross GD; Cain JA; Myones BL; Newman SL; Lachmann PJ
Complement; 1987; 4(2):61-74. PubMed ID: 3040332
[TBL] [Abstract][Full Text] [Related]
14. The effects of β-glucans on dendritic cells and implications for cancer therapy.
Albeituni SH; Yan J
Anticancer Agents Med Chem; 2013 Jun; 13(5):689-98. PubMed ID: 23092290
[TBL] [Abstract][Full Text] [Related]
15. The effects of beta-glucan on human immune and cancer cells.
Chan GC; Chan WK; Sze DM
J Hematol Oncol; 2009 Jun; 2():25. PubMed ID: 19515245
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy.
Weitberg AB
J Exp Clin Cancer Res; 2008 Sep; 27(1):40. PubMed ID: 18803849
[TBL] [Abstract][Full Text] [Related]
17. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
18. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan.
Allendorf DJ; Yan J; Ross GD; Hansen RD; Baran JT; Subbarao K; Wang L; Haribabu B
J Immunol; 2005 Jun; 174(11):7050-6. PubMed ID: 15905548
[TBL] [Abstract][Full Text] [Related]
19. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
20. Modulation of animal and human hematopoiesis by β-glucans: a review.
Hofer M; Pospíšil M
Molecules; 2011 Sep; 16(9):7969-79. PubMed ID: 21921869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
